The COVID-19 Clinical Spectrum and the Effect of Associated Comorbidities on Illness Severity in the North Indian Population: A Cross-Sectional Study

Mahak Lamba 1, Praveen Raman Mishra 2, Rahul Verma 3, Akash Bharti 4, VPS Punia 4, Shaavi Mittal 4

1. Internal Medicine, King George's Medical University, Lucknow, IND 2. Internal Medicine, All India Institute of Medical Sciences, Gorakhpur, IND 3. Respiratory Medicine, School of Medical Sciences & Research, Sharda University, Greater Noida, IND 4. Internal Medicine, School of Medical Sciences & Research, Sharda University, Greater Noida, IND

Corresponding author: Akash Bharti, akash.bharti@sharda.ac.in

Abstract

Background: The activity level of the 2019 novel coronavirus (2019-nCoV) or coronavirus disease 2019 (COVID-19), as it is now called, is considered low. Despite early preventive lockdown measures and a massive vaccination drive, almost the entire adult population in India will have been vaccinated at least once by the beginning of 2022 (2,072,946,593 till 11 August 2022). There is still concern about a pan-India outbreak and threat due to newly emerging pathogenic strains. The goal of this study is to find out how common various presenting complaints are in COVID-19 patients as well as how comorbidities affect the severity of the illness.

Methods: This cross-sectional observational study was conducted from December 2020 to January 2021 at a tertiary care hospital’s department of internal medicine in North India. The study included 237 patients who were COVID-19-positive and were admitted to our hospital after providing informed consent. They were classified into three groups: mild, moderate, and severe.

Results: Fever was the most common presenting symptom, affecting 84.4% of the population, while diarrhoea was the least common, affecting only 3.4% of the population. Fever, cough, sore throat, headache, and breathlessness were significantly correlated with the severity of the illness. Gastrointestinal symptoms like diarrhoea did not have any significant correlation with the severity of the illness. The severity of illness was statistically related to comorbidities such as hypertension, diabetes, coronary artery disease, chronic kidney disease, and chronic obstructive pulmonary disease.

Conclusion: Males were more likely to develop more serious illnesses. However, the correlation was not statistically significant. The number of comorbid conditions and the severity of the illness were found to have a fair and significant relationship. None of the diarrhoea symptoms were related to the severity of the illness.

Introduction

The 2019 novel coronavirus (2019-nCoV) or coronavirus disease 2019 (COVID-19), as it is now called, is rapidly spreading worldwide from its place of origin in Wuhan city of Hubei province of China [1]. The 2019-nCoV has a close similarity to bat coronaviruses, and it has been postulated that bats are the primary source. While the origin of the 2019-nCoV is still being investigated, current evidence suggests that spread to humans occurred via transmission from wild animals illegally sold in the Huanan Seafood Wholesale Market [2]. The pandemic has been renamed SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) due to its resemblance to severe acute respiratory syndrome [3,4]. The WHO declared COVID-19 a global pandemic on 11th March 2020 [5].

The severe acute respiratory syndrome outbreak was encountered in 2005, and, more recently, there was an outbreak of a related but different coronavirus, the Middle East respiratory syndrome coronavirus [6]. The primary coronavirus, discovered in bats in 1957, rarely infects humans and is found in animals such as bats, camels, and cats rather than humans or other mammals. They later mutated, causing the disease to infect rats, cows, pigs, mice, cats, dogs, horses, and turkeys. Cough and cold were common symptoms of the first human coronavirus discovered in the 1960s [7].

The enormity of symptoms and clinical manifestations observed in COVID-19 patients displayed a vast array of inter-individual differences. According to a meta-analysis by Sanyayolu et al., conducted in 2020, the most common symptom during COVID-19 was fever followed by dry cough [8]. It has been observed that...

Keywords: coronavirus disease 2019, covid-19, comorbidities, coronary artery disease, chronic kidney disease, ckd, cadi, hypertension, diabetes, severity

Categories: Internal Medicine, Medical Education, Public Health
most of the severely affected patients also had pre-existing comorbidities such as diabetes, cardiovascular conditions, and hypertension [8]. It was displayed that a higher probability of getting admitted to intensive care units also had a high mortality rate [9,10].

It is therefore required to evaluate the symptoms, mortality rates, patient profiles, and severity of the illness in the pre-vaccination era to assess early detection and appropriate treatment of critical cases. This is an invaluable asset to the healthcare system in India, which displays immense socio-economic and cultural diversity. Accordingly, this study aims to understand the prevalence of symptoms, comorbidities, and mortality rates in the pre-vaccination era and how they can be utilized to prevent future COVID-19 outbreaks.

**Materials And Methods**

This cross-sectional observational study lasted 62 days, from December 2020 to January 2021. The study focused on COVID-19 cases admitted to Sharda Hospital in Greater Noida, Uttar Pradesh, India. All patients diagnosed with COVID-19 admitted to Sharda Hospital and willing to participate in this study were enrolled in the study. Patients under the age of 15 and those who refused to participate were excluded from the study.

The prevalence of fever was found to be 88.7% during hospitalization among diagnosed cases of COVID-19, according to a study by Guan et al. [11]. The sample size was calculated using the formula: 

\[ n = \frac{Z^2pq}{d^2} \]

where Z is the ordinate of standard normal distribution at \( \alpha \)% level of significance (1.96 at \( \alpha = 5\% \) level of significance), p is the observed prevalence, q = 100 - p, and d is the margin of error (5%). According to the calculation, 154 subjects were required for the study. During the study, we were able to recruit 237 patients for the study.

All cases of COVID-19 infections underwent the nasopharyngeal swab test, which was evaluated using reverse transcription polymerase chain reaction for the presence of the COVID-19 virus. All the patients included in the study underwent a thorough history taking, which included demographic parameters such as age, gender, and area of residence, i.e., urban or rural, and a rigorous evaluation for detection of various symptoms of COVID-19 infections such as fever, chills/rigour, cough, fatigue, anorexia, myalgia, sore throat, and rhinorrhea. Other comorbid illnesses such as cardiovascular disease, diabetes mellitus, hypertension, chronic lung disease, chronic kidney disease, cancer, and obesity were also evaluated in all cases. Patients were classified based on the severity of symptoms [12], as shown in Table 1.

| Severity of symptoms | Description                                                                 |
|----------------------|-----------------------------------------------------------------------------|
| Mild                 | Low-grade fever, nausea, vomiting, and diarrhoea, no alteration in mental status, and immunocompetent |
| Moderate             | Respiratory rate greater than 30 breaths per minute, SpO2 greater than 93%, PaO2/FiO2 greater than 300, and pulmonary infiltrates greater than 50% within 24 to 48 hours |
| Severe               | Septic shock and MODS are all examples of critical respiratory failure (requiring mechanical ventilation) |

**TABLE 1: Severity of symptoms**

SpO2: oxygen saturation; PaO2: partial pressure of oxygen; FiO2: fraction of inspired oxygen; MODS: multiple organ dysfunction syndrome.

Laboratory investigations included chest X-ray, complete blood count, renal function test, liver function test, electrocardiography, blood sugar, and body mass index calculation.

**Statistical analysis**

Data were gathered and tabulated using Microsoft Excel 2007 (Microsoft Corporation, Redmond, WA) and analysed using the statistical software package SPSS version 26.0 (IBM Corp., Armonk, NY). The mean and standard deviation (SD) of the quantitative parametric data were presented. Percentages and proportions were used to represent qualitative data. As a means of determining significance, the chi-square test was used to compare categorical variables. Other descriptive statistics like ANOVA and independent t-test were employed to compare continuous data. A p-value of <0.05 was considered to be statistically significant.

**Results**

The mean ± SD of age among the study participants was 37.89 ± 16.10 years. Maximum subjects were between the age group of 21-30 years (32.1%), followed by 31-40 years (19.8%) and 41-50 years (14.8%). Approximately 14.3% of the subjects were asymptomatic. Of the patients, 84.4% had a fever, 59.9% had a cough, 40.5% had a sore throat, 21.5% had a headache, 26.6% had breathlessness, and 3.4% had diarrhoea. Comorbidities, namely, hypertension, diabetes, coronary artery disease, chronic kidney disease, and chronic obstructive pulmonary disease (COPD) accounted for 8.4%, 6.8%, 2.1%, 2.5%, and 3.4% of the study population, respectively (Table 2).
| Variable                        | Frequency | Percentage |
|--------------------------------|-----------|------------|
| **Age group (in years)**       |           |            |
| 10-20                          | 25        | 10.5       |
| 21-30                          | 76        | 32.1       |
| 31-40                          | 47        | 19.8       |
| 41-50                          | 35        | 14.8       |
| 51-60                          | 32        | 13.5       |
| 61-70                          | 10        | 4.2        |
| 71-80                          | 9         | 3.8        |
| >80                            | 3         | 1.3        |
| **Gender**                     |           |            |
| Male                           | 155       | 65.4       |
| Female                         | 82        | 34.6       |
| **Asymptomatic**               |           |            |
| Yes                            | 34        | 14.3       |
| No                             | 203       | 85.7       |
| **Fever**                      |           |            |
| Yes                            | 200       | 84.4       |
| No                             | 37        | 15.6       |
| **Cough**                      |           |            |
| Yes                            | 142       | 59.9       |
| No                             | 95        | 40.1       |
| **Sore throat**                |           |            |
| Yes                            | 96        | 40.5       |
| No                             | 141       | 59.5       |
| **Headache**                   |           |            |
| Yes                            | 51        | 21.5       |
| No                             | 186       | 78.5       |
| **Breathlessness**             |           |            |
| Yes                            | 63        | 26.6       |
| No                             | 174       | 73.4       |
| **Diarrhoea**                  |           |            |
| Yes                            | 8         | 3.4        |
| No                             | 229       | 96.6       |
| **Acute respiratory distress syndrome** | | |
| Yes                            | 24        | 10.1       |
| No                             | 213       | 89.9       |

**TABLE 2: Distribution of demographic variables among the study participants**
The distribution of comorbidities was found to be the same in asymptomatic and symptomatic individuals. When different comorbidities were compared between the asymptomatic and symptomatic groups using the chi-square test, an insignificant difference was found at p > 0.05 (Table 3).

| Comorbidities          | Asymptomatic (n = 34), N (%) | Symptomatic (n = 203), N (%) | P-value |
|------------------------|------------------------------|-----------------------------|---------|
| Hypertension           |                              |                             |         |
| Present                | 1 (2.9%)                     | 19 (9.36%)                  | 0.21    |
| Absent                 | 33 (97.1%)                   | 184 (90.64%)                |         |
| Diabetes mellitus      |                              |                             |         |
| Present                | 0                            | 16 (7.9%)                   | 0.09    |
| Absent                 | 34 (100%)                    | 187 (92.1%)                 |         |
| Coronary artery disease|                              |                             |         |
| Present                | 0                            | 5 (2.5%)                    | 0.355   |
| Absent                 | 34 (100%)                    | 198 (97.5%)                 |         |
| Chronic kidney disease |                              |                             |         |
| Present                | 1 (2.9%)                     | 5 (2.5%)                    | 0.87    |
| Absent                 | 33 (97.1%)                   | 198 (97.5%)                 |         |
| Chronic obstructive pulmonary disease | | | |
| Present                | 0                            | 8 (3.9%)                    | 0.24    |
| Absent                 | 34 (100%)                    | 195 (96.1%)                 |         |

**TABLE 3: Distribution of comorbidities with symptoms of the study participants**

Mild, moderate, and severe illness was found among 68, 4, and 10 females and 118, 18, and 19 males, respectively. Hence, the severity of illness was found to be more among males as compared to females, as shown in Figure 1.

**FIGURE 1: Distribution of gender with the severity of illness among the study participants**

Fever, cough, sore throat, headache, and breathlessness were significantly correlated with the severity of the illness. Gastrointestinal symptoms like diarrhoea did not have any significant correlation with the severity of the illness (Figure 2).
The severity of illness was statistically related to comorbidities such as hypertension, diabetes, coronary artery disease, chronic kidney disease, and COPD. Patients with severe illness had a higher prevalence of hypertension than those with mild or moderate illness (p = 0.001). Patients with severe illness had a higher prevalence of diabetes than those with mild or moderate illness (p = 0.001). Patients with severe illnesses had a higher prevalence of coronary artery disease than patients with mild or moderate illness (p = 0.002). Patients with severe illness had a higher prevalence of chronic kidney disease than patients with mild illness (p = 0.001), as shown in Table 4.

| Comorbidities          | Mild, N (%)  | Moderate, N (%) | Severe, N (%) | P-value |
|------------------------|--------------|-----------------|---------------|---------|
| **Hypertension**       |              |                 |               |         |
| Present                | 4 (2.2%)     | 5 (22.7%)       | 11 (37.9%)    | <0.001  |
| Absent                 | 182 (97.8%)  | 17 (77.3%)      | 18 (62.1%)    |         |
| **Diabetes mellitus**  |              |                 |               |         |
| Present                | 6 (3.2%)     | 2 (9.1%)        | 8 (27.6%)     | <0.001  |
| Absent                 | 180 (96.8%)  | 20 (90.9%)      | 21 (72.4%)    |         |
| **Coronary artery disease** |          |                 |               | 0.002   |
| Present                | 1 (0.5%)     | 1 (4.5%)        | 3 (10.3%)     |         |
| Absent                 | 185 (99.5%)  | 21 (95.5%)      | 26 (89.7%)    |         |
| **Chronic kidney disease** |           |                 |               | <0.001  |
| Present                | 1 (0.5%)     | 0               | 5 (17.2%)     |         |
| Absent                 | 185 (99.5%)  | 22 (100%)       | 24 (82.8%)    |         |
| **Chronic obstructive pulmonary disease** |   |                 |               | <0.001  |
| Present                | 2 (1.1%)     | 1 (4.5%)        | 5 (17.2%)     |         |
| Absent                 | 184 (98.9%)  | 21 (95.5%)      | 24 (82.8%)    |         |

**TABLE 4: Distribution of comorbidities with the severity of illness among the study participants**

All laboratory parameters evaluated were found to be elevated in patients suffering from a severe illness as compared to mild and moderate illness (Table 5).
Laboratory parameters | Mild (mean ± SD) | Moderate (mean ± SD) | Severe (mean ± SD) | P-value
--- | --- | --- | --- | ---
D-dimer | 0.89 ± 0.88 | 3.69 ± 2.10 | 7.44 ± 2.72 | <0.001
CRP | 62.95 ± 18.09 | 84.73 ± 29.41 | 109.07 ± 40.42 | <0.001
Ferritin | 229.09 ± 62.24 | 564.23 ± 150.42 | 870.41 ± 130.59 | <0.001
IL-6 | 4.47 ± 3.30 | 17.18 ± 8.43 | 41.52 ± 7.66 | <0.001
SPO2 | 0.98 ± 0.13 | 0.94 ± 0.02 | 0.91 ± 0.03 | 0.52
RR | 18.97 ± 2.73 | 22.32 ± 2.95 | 25.45 ± 3.54 | <0.001
SGPT | 49.80 ± 5.79 | 72.09 ± 24.11 | 132.07 ± 52.34 | <0.001
SGOT | 55.65 ± 5.69 | 77.09 ± 25.45 | 139.45 ± 53.58 | <0.001
TLC | 12170.97 ± 2417.86 | 14120.91 ± 4440.43 | 15757.93 ± 4243.20 | <0.001
CTSS | 3.02 ± 1.91 | 9.82 ± 1.79 | 19.00 ± 2.86 | <0.001

**TABLE 5:** Distribution of laboratory parameters with the severity of illness among the study participants

CRP: C-reactive protein; IL-6: interleukin-6; SPO2: oxygen saturation; RR: respiratory rate; SGPT: serum glutamic pyruvic transaminase; SGOT: serum glutamic oxaloacetic transaminase; TLC: total leucocyte count; CTSS: CT severity score.

C-reactive protein (CRP), ferritin, interleukin-6 (IL-6), respiratory rate (RR), serum glutamic pyruvic transaminase (SGPT), serum glutamic oxaloacetic transaminase (SGOT), total leucocyte count (TLC), and CT severity score (CTSS) were all found to be significantly higher in symptomatic patients as compared to asymptomatic patients (Table 6). To calculate CTSS, according to the anatomic structure, 18 segments of both lungs were divided into 20 regions, in which the posterior apical segment of the left upper lobe was subdivided into apical and posterior segmental regions, whereas the anteromedial basal segment of the left lower lobe was subdivided into anterior and basal segmental regions. The lung opacities in all of the 20 lung regions were subjectively evaluated on chest CT images using a system attributing scores of 0, 1, and 2 if parenchymal opacification involved 0%, less than 50%, or equal to or more than 50% of each region, respectively. The CTSS was defined as the sum of the individual scores in the 20 lung segment regions, which may range from 0 to 40 points [13].

Laboratory parameters | Asymptomatic (n = 34) | Symptomatic (n = 203) | P-value
--- | --- | --- | ---
D-dimer | 0.63 ± 0.75 | 2.19 ± 2.74 | <0.001
CRP | 56.03 ± 9.79 | 73.05 ± 29.10 | <0.001
Ferritin | 226.41 ± 119.32 | 357.48 ± 246.27 | <0.001
IL-6 | 3.03 ± 5.51 | 11.38 ± 13.67 | <0.001
SPO2 | 0.98 ± 0.008 | 0.98 ± 0.19 | 0.52
RR | 17.53 ± 1.56 | 20.50 ± 3.69 | <0.001
SGPT | 47.21 ± 5.08 | 64.40 ± 35.73 | <0.001
SGOT | 53.12 ± 5.12 | 70.36 ± 36.48 | <0.001
TLC | 9805.88 ± 2057.35 | 13290.84 ± 3044.26 | <0.001
CTSS | 3.02 ± 1.91 | 6.39 ± 1.57 | <0.001

**TABLE 6:** Distribution of laboratory parameters with asymptomatic individuals among the study participants

CRP: C-reactive protein; IL-6: interleukin-6; SPO2: oxygen saturation; RR: respiratory rate; SGPT: serum glutamic pyruvic transaminase; SGOT: serum glutamic oxaloacetic transaminase; TLC: total leucocyte count; CTSS: CT severity score.
Discussion

The clinical and epidemiological characteristics of 237 COVID-19 patients in the tropical region of North India reveal a variety of patterns that can aid in the management of COVID-19 patients and provide a platform for developing strategies for improving public health strategies, which could help us to flatten the epidemic curve and decelerate COVID-19 disease explosion. The majority of the patients in the sample (158, 66.7%) were found to be the most severely affected, with the majority of them being between the ages of 20 and 49 years. In this study, the severity of illness was reported more in males as compared to females. Similar male dominance was revealed by Singh et al. [14].

During the study period, no home quarantine was permitted in Uttar Pradesh, so the majority of patients were admitted to a quarantine centre or a COVID-19-dedicated hospital. In this study, the most common symptom was fever, followed by cough and sore throat. Similarly, Guan et al. reported fever (88.7%) as the most common symptom [11]. Our study had a higher prevalence of fever and cough compared to Singh et al. but a lower percentage of fever than those reported by Wang et al. [14,15]. The presence of similar signs and symptoms in both the temperate Wuhan region of China and the tropical region of India lends credence to the idea that these signs and symptoms could be used as a first public screening measure and tool to test for SARS-CoV-2 infection suspects.

Of our study participants, 8.4% had hypertension, 6.8% had diabetes, 2.1% had coronary artery disease, 2.5% had chronic kidney disease, and 3.4% had COPD. Approximately similar findings were revealed by Singh et al. [14]. Diabetes was linked to a two-fold increase in COVID-19 mortality and severity compared to non-diabetics in Kumar et al.'s study [16]. According to Singh et al., the most common comorbidities associated with mortality were hypertension and chronic kidney disease [14].

A population-based surveillance report via COVID-19-Associated Hospitalization Surveillance Network reported clinical data on 1478 COVID-19-positive patient hospitalizations. Among the 1478 patients studied, 12% of adults showed clinical data of underlying medical conditions with the most prevalent being hypertension (49.7%) and obesity a close second (48.5%). Other medical conditions included chronic lung disease (54.6%), diabetes mellitus (28.3%), and cardiovascular diseases (27.8%) [17]. This was similar to our study. In a study by Filardo et al., advanced age, male sex, and obesity were the main factors associated with mortality. Cardiovascular and renal comorbidities were not associated with mortality in an adjusted analysis, perhaps owing to the limited sample size and the inability to detect these associations [18].

Due to COVID-19 being a relatively new disease, the data available were limited. However, from the cases that emerged, it was observed that comorbidities increase the chances of infection. Based on current information and clinical expertise, a generalization can be made that those with comorbidities have more symptomatic COVID. The elderly, a vulnerable population, with chronic health conditions such as diabetes and cardiovascular or lung disease are not only at a higher risk of developing severe illness but are also at an increased risk of death if they become ill. People with underlying uncontrolled medical conditions such as diabetes, hypertension, lung, liver, and kidney disease, and patients taking steroids chronically are at increased risk of COVID-19 infection [11,14].

In this study, IL-6 was found to be significantly more in symptomatic as compared to asymptomatic patients. Chen et al. reported a similar finding with significant elevation in the level of inflammatory cytokine IL-6 in critically ill COVID-19 patients [2]. Similarly, Liu et al. showed that a higher serum level of IL-6 was an independent and reliable risk factor for COVID-19 patients and led to higher disease severity and mortality [19]. IL-6 is an important pro-inflammatory factor in the disease process of SARS-CoV-2. It contributes to COVID-19-associated cytokine storms, largely enhancing vascular permeability and impairing organ function. The SARS-CoV-2 virus replicates rapidly, triggering a storm characterized by increased levels of cytokines such as IL-6. Such an inflammatory response causes inflammation of the respiratory system and other bodily systems, with subsequent occurrence of acute respiratory distress syndrome or respiratory failure. Thus, estimation of IL-6 levels could be an important tool to assess disease severity in COVID-19 patients.

CTSS was found to be significantly more among symptomatic as compared to asymptomatic patients in this study. In a study by Raoufi et al., patients with lower CTSS had lower mortality [20]. According to Zayed et al., chest CT plays a segregate role in COVID-19 disease, adds an advantage in clinical data in triage, and highlights the decision of hospital admission [21].

Limitations

The major limitations of our study were that the prevalence of comorbidities was lower at an earlier age, and the sample population with comorbidities was small. Despite the study's inclusion of a sufficient number of COVID-19 patients, no significant associations between multiple comorbidities and mortality were found. The population was unvaccinated as India began vaccination on 16 January 2021.

Strength

The unique aspect of our study was the comparison of interleukin and CTSS scores among asymptomatic and
Conclusions
Males were more likely to develop more serious illnesses. The number of comorbid conditions and the severity of the illness were found to have a significant relationship. Fever, cough, sore throat, headache, and shortness of breath were found to be associated with a higher degree of illness. None of the diarrhoea symptoms were related to the severity of the illness. Hypertension, diabetes, coronary artery disease, chronic kidney disease, and COPD were all found to have statistically significant associations with illness severity.

Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethical Committee, School of Medical Sciences & Research, Sharda University approved submission to reference number SU/SMS & R/76/A/2020/42. The Institutional Ethical Committee, School of Medical Sciences & Research, Sharda University approved this study under reference number SU/SMS & R/76-A/2020/42. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References

1. de Wit E, van Doremalen N, Falzarano D, Munster VJ: SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016, 14:525-54. 10.1038/nrmicro.2016.81
2. Chen N, Zhou M, Dong X, et al.: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020, 395:507-13. 10.1016/S0140-6736(20)30211-7
3. Zhang C, Zheng W, Huang X, Bell EW, Zhou X, Zhang Y: Protein structure and sequence reanalysis of 2019-nCoV genome refutes snakes as its intermediate host and the unique similarity between its spike protein insertions and HIV-1. J Proteome Res. 2020, 19:1551-60. 10.1021/acs.jproteome.0c00129
4. Zhou P, Yang XL, Wang XG, et al.: A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020, 579:270-3. 10.1038/s41586-020-2012-7
5. World Health Organization. Coronavirus disease 2019 (COVID-19): situation report, 90. (2020). Accessed: February 19, 2022: https://apps.who.int/iris/handle/10665/3531859.
6. Chathappady House NN, Palissy M, Sebastian H: Coronavirus: A review on SARS, MERS and COVID-19. Microbiol Insights. 2021, 14:10.1177/11786561211002481
7. Kahn JS, McIntosh K: History and recent advances in coronavirus discovery. Pediatr Infect Dis J. 2005, 24:5225-7. 10.1097/01.inf.0000188166.17324.60
8. Lakshmimaran R, BM, G V, Arjun Kumar KV, Wahl B, Lewnard JA: SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study. Lancer Infect Dis. 2021, 21:1665-76. 10.1016/S1473-3099(21)00595-5
9. Sanyoolu A, Okorie C, Marinkovic A, et al.: Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020, 2,1069-76. 10.1002/sccm.202001056-4
10. Zhang G, Hu C, Luo L, et al.: Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China. J Clin Virol. 2020, 127:104364. 10.1016/j.jcv.2020.104364
11. Guan WJ, Ni ZY, Hu Y, et al.: Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020, 382:1708-20. 10.1056/NEJMoa2002052
12. Guidelines on operationalization of COVID care services for children and adolescents by Government of India, Ministry of Health. (2022). Accessed: March 21, 2022: https://www.mohfw.gov.in/pdf/GuidelinesonOperationalizationofCoVIDCareServicesforChildrenandAdolescents14062021.pdf
13. Yang R, Li X, Liu J, et al.: Chest CT severity score: an imaging tool for assessing severe COVID-19. Radiol Cardiothorac Imaging. 2020, 2:e200047. 10.1148/ryct.2020200047
14. Singh DK, Garg A, Bagri S, Choudhary P, Kubert D, Kem AK: COVID 19 presentation and effect of associated co-morbidities on severity of illness at a dedicated COVID hospital in North India. J Res Med Dent Sci. 2021, 9:49-54.
15. Wang D, Hu B, Hu C, et al.: Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020, 323:1061-9. 10.1001/jama.2020.1585
16. Kumar A, Arora A, Sharma P, et al.: Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab Syndr. 2020, 14:535-45. 10.1016/j.dsx.2020.04.044
17. Garg S, Kim L, Whitaker M, et al.: Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-19, 14 states, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020, 69:155-64. 10.15585/mmwr.mm6915e5
18. Filardo TD, Khan MR, Krawczyk N, et al.: Comorbidity and clinical factors associated with COVID-19 critical illness and mortality at a large public hospital in New York City in the early phase of the pandemic (March-April 2020). PLoS One. 2020, 15:e0242760. 10.1371/journal.pone.0242760
19. Liu Z, Li J, Chen D, et al.: Dynamic interleukin-6 level changes as a prognostic indicator in patients with COVID-19. Front Pharmacol. 2020, 11:1093. 10.3389/fphar.2020.01093
20. Raoofi M, Salavi Naini SAA, Arzani Z, et al.: Correlation between chest computed tomography scan findings and symptomatic patients in a resource-limiting setting.
21. Zayed NE, Bessar MA, Lutfy S: CO-RADS versus CT-SS scores in predicting severe COVID-19 patients: retrospective comparative study. Egypt J Bronchol. 2021, 15:13. 10.1186/s43168-021-00060-3